Botulinum Toxin Type a Injection to Prevent Keloid Recurrence

Summary

The prospective, split-scar, double-blind, randomized controlled study will enroll the patients who are older than 20 years with progressive keloid lesion which is symmetric. Botulinum toxin A will be injected into half of each keloid revision wound immediately after skin closure. The scars will be assessed at 1-year follow-up with Vancouver Scar Scale (VSS), Patient and Observer Scar Assessment Scale (POSAS), and the Cutometer.

Timeline

Start

2020-10-13

Primary completion

2024-03-20

Completion

2024-03-20

Drugs

Indications